Novartis AG

Industry / private company


Location: Basel, Switzerland (CH) CH

ISNI: 0000000115159979

ROR: https://ror.org/02f9zrr09

Show on Map:


close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

A multi-sensor wearable system for the assessment of diseased gait in real-world conditions (2023) Salis F, Bertuletti S, Bonci T, Caruso M, Scott K, Alcock L, Buckley E, et al. Journal article Quality of life with ribociclib versus abemaciclib as first-line treatment of HR+/HER2− advanced breast cancer: a matching-adjusted indirect comparison (2023) Rugo HSS, Harmer V, O'Shaughnessy J, Jhaveri K, Tolaney SMM, Cardoso F, Bardia A, et al. Journal article Immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination in patients receiving secukinumab: a literature review (2023) Gisondi P, Simon D, Alarcon I, Pournara E, Puig L Journal article, Review article Quantification of pre-existing radiographic damage and its relationship with joint activity and long-term clinical outcomes with secukinumab therapy in patients with psoriatic arthritis (2022) Mease P, Van Der Heijde D, Kirkham B, Schett G, Orbai AM, Ritchlin C, Merola JF, et al. Journal article Design and validation of a multi-task, multi-context protocol for real-world gait simulation (2022) Scott K, Bonci T, Salis F, Alcock L, Buckley E, Gazit E, Hansen C, et al. Journal article Gait Variability to Phenotype Common Orthopedic Gait Impairments Using Wearable Sensors (2022) Kushioka J, Sun R, Zhang W, Muaremi A, Leutheuser H, Odonkor CA, Smuck M Journal article Chemoinformatics and artificial intelligence colloquium: progress and challenges in developing bioactive compounds (2022) Bajorath J, Chávez-Hernández AL, Duran-Frigola M, Fernández-de Gortari E, Gasteiger J, López-López E, Maggiora GM, et al. Journal article Matching adjusted indirect comparison of PFS & OS comparing ribociclib plus letrozole vs palbociclib plus letrozole as first-line treatment of HR+/HER2-ABC: Analysis based on updated PFS & final OS results of MONALEESA-2 & PALOMA-2 (2022) Jhaveri K, O'Shaughnessy J, Fasching P, Cardoso F, Tolaney S, Hamilton E, Sharma VK, et al. Conference contribution Prognostic potential of baseline HRQoL in advanced and metastatic renal cell carcinoma (2022) Gruenwald V, Goebell P, Schostak M, Welslau M, Doehn C, Degenkolbe E, Ehness R, et al. Conference contribution Impact of Siponimod on Enteric and Central Nervous System Pathology in Late-Stage Experimental Autoimmune Encephalomyelitis (2022) Weier A, Enders M, Kirchner P, Ekici AB, Bigaud M, Kapitza C, Wörl J, Kuerten S Journal article